Results 101 to 110 of about 51,741 (305)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

medRxiv, 2021
Using isolates of SARS-CoV-2 WT, Beta, Delta and most importantly Omicron we studied the capability of the BNT162b2 vaccine given in two or three doses to neutralize major SARS-CoV-2 variants of concern (VOC). We demonstrate low neutralization efficiency
I. Nemet, L. Kliker, Y. Lustig, N. Zuckerman, O. Erster, Carmit Cohen, Y. Kreiss, S. alroy-Preis, G. Regev-Yochay, E. Mendelson, M. Mandelboim   +10 more
semanticscholar   +1 more source

Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan

Vaccines, 2022
Analysis of longitudinal dynamics of humoral immune responses to the BNT162b2 COVID-19 vaccine might provide useful information to predict the effectiveness of BNT162b2 in preventing SARS-CoV-2 infection.
Atsuhiko Sakamoto, Michinobu Yoshimura, Ryota Itoh, Ryo Ozuru, Kazunari Ishii, Yusuke Sechi, Shigeki Nabeshima, Kenji Hiromatsu   +7 more
doaj   +1 more source

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial [PDF]

, 2023
Neutralizing antibodies; Protein-based vaccine; SARS-CoV-2Anticuerpos neutralizantes; Vacuna a base de proteínas; SARS-CoV-2Anticossos neutralitzants; Vacuna a base de proteïnes; SARS-CoV-2Background: A SARS-CoV-2 protein-based heterodimer vaccine, PHH ...
Barreiro, Antonio, Cañete, Manuel, Corominas Garcia, Júlia, Garriga, Carme, Martínez-Gómez, Xavier, Moros, Alexandra, Otero-Romero, Susana, Prenafeta, Antoni, Sans-Pola, Carla   +8 more
core   +1 more source

Myocarditis after BNT162b2 vaccination in a healthy male

The American Journal of Emergency Medicine, 2021
Myocarditis following mRNA COVID-19 vaccination has recently been reported to health authorities in the United States and other countries. Cases predominately occur in young adult males within four days following the second dose of either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines.
Watkins, Kevin, Griffin, Gregory, Septaric, Kristen, Simon, Erin L.   +3 more
openaire   +2 more sources

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination [PDF]

iScience, 2022
Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower efficacy of this regimen.
Bauswein, Markus, Peterhoff, David, Plentz, Annelie, Hiergeist, Andreas, Wagner, Ralf, Gessner, André, Salzberger, Bernd, Schmidt, Barbara, Bauernfeind, Stilla   +8 more
openaire   +4 more sources

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

American Journal of Transplantation, 2021
COVID‐19 is associated with increased morbidity and mortality in transplant recipients. There are no efficacy data available regarding these patients with any of the available SARS‐CoV‐2 vaccines.
A. Grupper, L. Rabinowich, D. Schwartz, I. Schwartz, M. Ben-Yehoyada, Moshe Shashar, E. Katchman, T. Halperin, D. Turner, Y. Goykhman, O. Shibolet, S. Levy, I. Houri, R. Baruch, H. Katchman   +14 more
semanticscholar   +1 more source

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile

Frontiers in Public Health, 2023
IntroductionSevere acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million ...
Diego A. Díaz-Dinamarca, Pablo Díaz, Gisselle Barra, Rodrigo Puentes, Loredana Arata, Jonnathan Grossolli, Boris Riveros-Rodriguez, Luis Ardiles, Julio Santelises, Julio Santelises, Valeria Vasquez-Saez, Daniel F. Escobar, Daniel Soto, Cecilia Canales, Janepsy Díaz, Liliana Lamperti, Daniela Castillo, Mychel Urra, Felipe Zuñiga, Valeska Ormazabal, Estefanía Nova-Lamperti, Rosana Benítez, Alejandra Rivera, Claudia P. Cortes, Claudia P. Cortes, Claudia P. Cortes, María Teresa Valenzuela, Heriberto E. García-Escorza, Abel E. Vasquez, Abel E. Vasquez, Abel E. Vasquez   +30 more
doaj   +1 more source

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients

medRxiv, 2021
Background The SARS-CoV-2 Omicron variant, designated as a Variant of Concern(VOC) by the World Health Organization, carries numerous spike protein mutations which have been found to evade neutralizing antibodies elicited by COVID-19 vaccines.
Lu Lu, B. Mok, Lin-lei Chen, Jim Kh H. Chan, O. Tsang, B. Lam, V. W. Chuang, A. W. Chu, W. Chan, J. D. Ip, Brian Chun-Yuan Chan, Ruiqi Zhang, C. Yip, V. Cheng, Kwok-Hung Chan, D. Jin, I. Hung, K. Yuen, Honglin Chen, K. To   +19 more
semanticscholar   +1 more source

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

Vaccines, 2022
Given the increasing anti-vaccine movements erroneously touting vaccine danger, this review has investigated the rare adverse events potentially associated with BNT162b2 (Pfizer-BioNTech), an mRNA vaccine against the severe acute respiratory distress ...
Shin-Jie Yong, Alice Halim, Michael Halim, Abbas Al Mutair, Saad Alhumaid, Jehad Al-Sihati, Hawra Albayat, Mohammed Alsaeed, Mohammed Garout, Reyouf Al Azmi, Noor Aldakheel, Abeer N. Alshukairi, Hani A. Al Ali, Adel A. Almoumen, Ali A. Rabaan   +14 more
doaj   +1 more source

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression:a longitudinal cohort study [PDF]

, 2022
Background: COVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce.
Barker, Jonathan N, Baudry, David, Bechman, Katie, Brown, Matthew A, Cope, Andrew P, Dasandi, Tejus, Domingo-Vila, Clara, Doores, Katie J, Galloway, James B, Graham, Carl, Khan, Hataf, Lechmere, Thomas, Mahil, Satveer K, Malim, Michael H, Meynell, Freya, Norton, Sam, Pollock, Emily, Raharja, Antony, Smith, Catherine H, Sychowska, Kamila, Tree, Timothy   +20 more
core   +2 more sources